M. Miller

发表

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

E. Winer, G. Hortobagyi, K. Blackwell, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer.

H. Rugo, H. Iwata, D. Juric, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1.

H. Rugo, H. Iwata, D. Juric, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

E. Winer, G. Hortobagyi, K. Blackwell, 2019 .

Abstract PD2-05: Biomarker analysis by baseline circulating tumor DNA alterations in the MONALEESA-3 study

P. Neven, S. Chia, G. Jerusalem, 2019, Poster Discussion Abstracts.

Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.

A. Bardia, F. Meric-Bernstam, F. Penault-Llorca, 2016, Breast.

An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study).

S. Shousha, E. Lam, J. Stebbing, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Bone health management of Australian breast cancer survivors receiving hormonal therapy

B. Koczwara, R. Roberts, M. Miller, 2015, Internal medicine journal.

LBA1 First-line ribociclib + letrozole in postmenopausal Asian women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2

K. Blackwell, J. Kim, S. Verma, 2016 .

The Impact of Complementary and Alternative Medicines on Cancer Symptoms, Treatment Side Effects, Quality of Life, and Survival in Women With Breast Cancer—A Systematic Review

B. Koczwara, B. Koczwara, S. Leggett, 2015, Nutrition and cancer.

Abstract P4-22-16: First-line ribociclib + letrozole in patients with HR+, HER2– advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial

E. Winer, M. Campone, H. Burris, 2017 .

First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses.

G. Hortobagyi, L. Hart, C. Arteaga, 2018 .

Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).

E. Winer, G. Hortobagyi, K. Blackwell, 2017 .

Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib

G. Caponigro, S. Scherer, C. Germa, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of all-trans-retinoic acid and alpha-interferon in patients with advanced non-small cell lung cancer.

A. Rademaker, W. Gradishar, M. Kies, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).

G. Sonke, E. Simoncini, S. Spazzapan, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

breast cancer, locally advanced and metastaticFirst-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC)

E. Winer, G. Hortobagyi, K. Blackwell, 2016 .

Abstract P5-21-18: Subsequent treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received ribociclib + letrozole vs placebo + letrozole in the phase III MONALEESA-2 study

M. Campone, H. Burris, J. Beck, 2018 .